WALTHAM, Mass., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious ...

WALTHAM, Mass.–(BUSINESS WIRE)–Morphic Holding, Inc. (“Morphic”), a biopharmaceutical company discovering and developing oral small-molecule integrin therapeutics, today announced the closing of its ...

WALTHAM, Mass., May 03, 2023 (GLOBE NEWSWIRE) -- Morphic Holding, Inc. (MORF), a biopharmaceutical company developing a portfolio of oral integrin therapies for the treatment of serious chronic ...

Morphic Therapeutic has lost another Big Pharma partner. Eleven months after AbbVie walked away, Johnson & Johnson has delivered the killer blow to its own already-diminishing ties to the biotech. J&J ...

INDIANAPOLIS and WALTHAM, Mass., July 8, 2024 /PRNewswire/ -- Eli Lilly and Company (LLY) and Morphic Holding, Inc. (NASDAQ: MORF) today announced a definitive agreement for Lilly to acquire Morphic ...

Filed first IND of an oral integrin drug candidate, MORF-057, generated by Morphic’s MInT Platform and initiated first clinical study of MORF-057 in healthy volunteers in Phase 1 clinical trial of ...

Since Friday, Morphic Therapeutic MORF shares have plunged from $47.92 to $26.25 after the company announced the publication of an abstract discussing new EMERALD-1 phase 2a primary results at United ...

First orally available integrin inhibitor from MInT Platform to enter the clinicMORF-057, inhibitor of α4β7 integrin, in development to treat inflammatory bowel diseasePhase 1 program to assess safety ...

Morphic filed documents with the SEC Friday for a $86.25 million IPO. It plans to trade on Nasdaq with the ticker "MORF". A preclinical Waltham biotech co-founded by noted Harvard immunologist Tim ...

A company developing therapies around a family of receptors that control a wide variety of cellular processes has raised a new Series B funding round. Waltham, Massachusetts-based Morphic Therapeutic ...